Biocept shows positive results on liquid biopsy for detecting lung cancer mutations

February 26, 2016 – SAN DIEGO.  Biocept, Inc. announced that findings demonstrating the ability to reliably detect actionable genetic alterations used in the diagnosis, monitoring and treatment of patients with lung cancer using its blood-based biopsy was presented in a poster at the UCSD Moores Cancer Center Industry/Academia Translational Oncology Symposium held this week in San Diego. The poster, titled “High Sensitivity Detection of Rare EGFR Mutations with ctDNA Using Target-Selector Assays,” included data showing a high degree of concordance of Biocept’s assay with results from invasive tissue biopsy.

“The results of this study further demonstrate the ability of Biocept’s liquid biopsy platforms to detect the presence of key cancer-associated biomarkers, which can be used in aiding medical decision-making,” said Biocept’s Senior Vice President and Senior Medical Director Veena Singh, M.D. “In this study we compared the results from our Target-Selector™ using blood samples against tissue samples from 74 patients with lung cancer and found concordance of greater than 93%.  This high rate of concordance in conjunction with the high level of sensitivity in detecting acquired resistance mechanisms in lung cancer patients underscores the value of using our liquid biopsy platforms.”

“The ability of the Target-Selector™ assay to detect rare genetic events from blood has great utility when applied to patients with lung cancer, where it is often challenging to obtain a tissue sample,” said Biocept’s Senior Vice President and Chief Scientific Officer Lyle Arnold, Ph.D.  “It is rewarding to see these assays clinically validated and being utilized by physicians as an adjunct to solid tumor biopsies in patients with cancer.”

Biocept has a number of ongoing validation and clinical studies which are intended to demonstrate the performance and clinical utility of its liquid biopsy platform.  These studies focus on the detection of key predictive biomarkers in blood, as well as monitoring the concentrations of these biomarkers throughout therapy. 

Determining the presence of circulating tumor DNA (ctDNA) in blood, which is indicative of the presence of solid tumors, is the goal of assays known as “liquid biopsies.”  The use of a liquid biopsy is proving useful for monitoring a patient’s tumor burden and for guiding the personalized treatment of patients with cancer based on the presence of biomarkers associated with solid tumors.  Historically, solid tumor tissue obtained from surgical biopsies has been used routinely to detect the presence of key genomic biomarkers that can aid in the detection of cancer and in treatment decision-making.  The ability to detect these same biomarkers based on material shed from the tumor into the blood provides an alternative for physicians where a solid tumor biopsy is difficult or impractical to obtain, or poses a high risk to the patient.

SOURCE Biocept, Inc.